Osteoprotegerin-does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women?

Endokrynologia Polska

Volumn 58, Issue 1, 2007, Pages 7-10

  Holecki, Michal ^a   Zahorska Markiewicz, Barbara ^a   Janowska, Joanna ^a   Mizia Stec, Katarzyna ^a   Zak Golab, Agnieszka ^a   Olszanecka Glinianowicz, Magdalena ^a   Wojaczyñska Stanek, Katarzyna ^a   Nieszporek, Teresa ^a   Wiěcek, Andrzej ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

BMD; Bone turnover; Calcitropic hormones; Obesity; Osteoprotegerin

Indexed keywords

CALCIFEDIOL; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE;

ARTICLE; BLOOD; BODY MASS; CASE CONTROL STUDY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; RADIODENSITOMETRY;

BODY MASS INDEX; CALCIFEDIOL; CASE-CONTROL STUDIES; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MIDDLE AGED; OBESITY; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; PARATHYROID HORMONE;

EID: 34548379159     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Glass AR. Endocrine aspects of obesity. Med Clin North Am 1989; 73: 139-160.
2. Ravn P, Cizza G, Bjarnason NH et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 1999; 14: 1622-1627.
3. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: A new paradigim for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000; 11: 905-913.
4. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibitsosteoclastogenesis in vitro. Endocrinology 1989; 39: 1329-1337.
5. Known BS, Wang S, Udagawa N et al. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone formation. FASEB J 1998; 12: 845-854.
6. Akatsu T, Murakami T, Nishikawa M et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 1998; 250: 229-234.
7. Fuller K, Wong B, Fox S et al. TRANCE is necessary and sufficient for osteoblast mediated activation of bone resorption in osteoclast. J Exp Med 1998; 188: 997-1001.
8. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96: 3540-3546.
9. Holecki M, Zahorska-Markiewicz B, Nieszporek T et al. Impact of the mass-reductive therapy with orlistat on 25-(OH)-D3 and PTH concentration in sera of obese, menopausal women. Endokrynol Pol 2005; 56: 240-246.
10. Andersen T, Mc Nair P, Fogh-Andersen N et al. Increased parathyroid hormone as a consequence of changed complex binding plasma calcium in morbid obesity. Metabolism 1986; 35: 147-151.
11. Mosekilde L, Melsen I, Hessov I et al. Low serum levels of 1,25 dihydroxyvitamin D and histomorphometric evidence of osteomalacia after jejunostomy bypass for obesity. Gut 1980; 2: 624-631.
12. Seck T, Diel I, Bismar H et al. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. Eur J Endocrinol 2001; 145: 199-206.
13. Ostrowska Z, ̄wirska-Korczala K, Buntern B et al. Assessment of bone metabolism in obese women. Endocr Reg 1998; 32: 177-181.
14. Liel Y, Ulmer E, Shary J et al. Low circulating vitamin D in obesity. Calcif Tissue Int 1998; 43: 199-201.
15. Yano K, Tsuda E, Washida N et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14: 518-527.
16. Arrighi HM, Hsieh A, Wong H et al. Osteoprotegerin serum levels in healthy volunteers. Bone 1998; 23: T411.
17. Arrighi H, Khosla S, Melton LJ et al. The relationship between circulating osteoprotegerin and estrogen in postmenopausal women. J Bone Miner Res 2000; 15: M33-4.